Lung-MAP Protocol Expands Trial Access for Marginalized Groups miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
As compared to conventional, stand-alone clinical trials in advanced non-small cell lung cancer (NSCLC), the biomarker-driven Lung Cancer Master Protocol (Lung-MAP) has enrolled higher percentages of patients who are older, patients who are from rural or socioeconomically deprived areas, and patients who have Medicaid or no insurance.
Biomarker-driven protocol model broadens lung cancer trial access for some underrepresented groups medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients finchannel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finchannel.com Daily Mail and Mail on Sunday newspapers.
Researchers have begun enrolling patients in Pragmatica-Lung, an NCI-supported phase 3 study designed specifically to eliminate barriers to clinical trial accessibility and participation.The trial, also known as S2302, will evaluate a two-drug combination for patients with advanced non-small cell lung cancer. It will be among the first NCI-supported trials to use a pragmatic trial design aimed at